carvedilol has been researched along with Esophageal Varices in 56 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "136 patients with ACLF (with no or small esophageal varices and HVPG ≥ 12 mmHg) were randomized to either carvedilol (n = 66) or placebo arms (n = 70)." | 9.30 | Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial. ( Agarwal, PM; Bhardwaj, A; Choudhury, A; Jindal, A; Kainth, S; Kumar, G; Kumar, M; Maiwall, R; Mitra, LG; Saluja, V; Sarin, SK; Shasthry, SM, 2019) |
| "Carvedilol is safe and effective in delaying the progression of small to large oesophageal varices in patients with cirrhosis." | 9.24 | Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. ( Bhadoria, AS; Bhardwaj, A; Bhatia, V; Choudhary, A; Jindal, A; Kedarisetty, CK; Kumar, G; Kumar, M; Maiwall, R; Sarin, SK; Shasthry, SM; Vashishtha, C, 2017) |
| "To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices." | 8.98 | Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. ( Bendtsen, F; Gluud, LL; Hobolth, L; Jeyaraj, R; Morgan, MY; Zacharias, AP, 2018) |
| "In this prospective cohort study, 106 cirrhotic patients with high-risk esophageal varices in the derivation cohort received carvedilol prophylaxis, and completed paired measurements of hepatic venous pressure gradient, liver stiffness (LS), and spleen stiffness (SS) at the beginning and end of dose titration." | 7.91 | Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. ( Ahn, DW; Baik, SK; Jung, YJ; Kim, D; Kim, HY; Kim, MY; Kim, W; So, YH; Woo, H, 2019) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 6.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Propranolol was used for secondary UVB prophylaxis in 43 (75." | 5.72 | Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis. ( Cançado, GGL; Cardoso, JB; Couto, CA; de Abreu, ES; Faria, LC; Ferrari, TCA; Lima, AMC; Nardelli, MJ; Osório, FMF, 2022) |
| " First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome." | 5.41 | Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023) |
| "Cirrhotic patients with esophageal varices and with baseline HVPG > 12 mm Hg were prospectively randomized for primary prophylaxis to receive either carvedilol (group A, n = 110) or carvedilol plus simvastatin (group B, n = 110)." | 5.34 | Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial. ( Arora, V; Choudhary, A; Jindal, A; Kumar, G; Sarin, SK; Vijayaraghavan, R, 2020) |
| "136 patients with ACLF (with no or small esophageal varices and HVPG ≥ 12 mmHg) were randomized to either carvedilol (n = 66) or placebo arms (n = 70)." | 5.30 | Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial. ( Agarwal, PM; Bhardwaj, A; Choudhury, A; Jindal, A; Kainth, S; Kumar, G; Kumar, M; Maiwall, R; Mitra, LG; Saluja, V; Sarin, SK; Shasthry, SM, 2019) |
| "Carvedilol is safe and effective in delaying the progression of small to large oesophageal varices in patients with cirrhosis." | 5.24 | Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. ( Bhadoria, AS; Bhardwaj, A; Bhatia, V; Choudhary, A; Jindal, A; Kedarisetty, CK; Kumar, G; Kumar, M; Maiwall, R; Sarin, SK; Shasthry, SM; Vashishtha, C, 2017) |
| "Cirrhotic patients with esophageal varices were randomized to carvedilol 12." | 5.19 | Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial. ( Abid, S; Azam, Z; Hamid, S; Ismail, FW; Jafri, W; Khalid, A; Munir, SM; Parkash, O; Rauf, J; Shah, HA; Subhan, A, 2014) |
| "Patients with oesophageal varices undergoing measurement of HVPG before and under propranolol treatment (80-160 mg/day) were included." | 5.17 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. ( Ferlitsch, A; Heinisch, BB; Kramer, L; Payer, BA; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Schwabl, P; Trauner, M; Ulbrich, G, 2013) |
| "To assess the beneficial and harmful effects of carvedilol compared with traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices." | 4.98 | Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. ( Bendtsen, F; Gluud, LL; Hobolth, L; Jeyaraj, R; Morgan, MY; Zacharias, AP, 2018) |
| "The Beta-blockers Or Placebo for Primary Prophylaxis of oesophageal varices (BOPPP) trial is a 3-year phase IV, multi-centre clinical trial of investigational medicinal product (CTIMP) that aims to determine the effectiveness of carvedilol in the prevention of variceal bleeding for small oesophageal varices in patients with cirrhosis." | 4.12 | General practitioner perspectives on factors that influence implementation of secondary care-initiated treatment in primary care: Exploring implementation beyond the context of a clinical trial. ( Ahmed, H; Carter, B; Lawrence, V; Le Boutillier, C; McPhail, M; Patel, VC; Ward, C, 2022) |
| "In this prospective cohort study, 106 cirrhotic patients with high-risk esophageal varices in the derivation cohort received carvedilol prophylaxis, and completed paired measurements of hepatic venous pressure gradient, liver stiffness (LS), and spleen stiffness (SS) at the beginning and end of dose titration." | 3.91 | Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices. ( Ahn, DW; Baik, SK; Jung, YJ; Kim, D; Kim, HY; Kim, MY; Kim, W; So, YH; Woo, H, 2019) |
| "220 patients with known esophageal varices on upper GI endoscopy and no previous history of GI bleed were randomized to group A (Carvedilol) and group B (Propranolol)." | 3.30 | Comparison of carvedilol and propranolol for primary prophylaxis of esophageal variceal bleed in cirrhotic patients. ( Aneeza Ilyas, -; Khalid Mahmud Khan, -; Maria, -; Muhammad Adnan Iqbal, -; Muhammad Farooq Hanif, -; Nooman Gilani, -; Raja Omer Fiaz, -, 2023) |
| "Portal hypertension is the primary driver of decompensation, including the development of ascites, hepatic encephalopathy and variceal haemorrhage." | 3.01 | Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis. ( Gillespie, SL; Hanrahan, TP; Hayes, PC; Majumdar, A; Rockey, DC, 2023) |
| "Carvedilol is a non-selective beta-blocker (NSBB) acting on hyperdynamic circulation/splanchnic vasodilation and on intrahepatic resistance." | 3.01 | Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. ( La Mura, V; Reiberger, T; Turco, L; Vitale, G, 2023) |
| " Carvedilol-specific experience was also influenced by the manifestation of side effects and patient dosage routine." | 3.01 | Exploring patients' perceptions and experiences of treatments for the prevention of variceal bleeding: a qualitative study. ( Mathers, J; Poyner, C; Tripathi, D, 2021) |
| "Carvedilol is a good pharmaceutical alternative medicine to propranolol with lesser side-effects." | 2.87 | Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding. ( Abd ElRahim, AY; Elsharkawy, A; Fathalah, W; Fouad, R; Khairy, M; Khatamish, H; Khorshid, O; Moussa, M; Seyam, M, 2018) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 2.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Carvedilol is a vasodilating non-selective β-blocker with alpha-1 receptor and calcium channel antagonism." | 2.79 | Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding. ( Dickson, S; Forrest, EH; Gaya, DR; Hayes, PC; Leithead, JA; MacBeth, K; Mills, PR; Smith, L; Stanley, AJ; Suzuki, H; Tripathi, D; Young, D, 2014) |
| "Recurrent bleeding from esophageal varices occurred in 31 patients (51%) in the carvedilol group and in 26 patients (43%) in the N + I group (P = 0." | 2.77 | Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding. ( Chen, WC; Lo, GH; Wang, HM; Yu, HC, 2012) |
| "Carvedilol is an option for primary prophylaxis in patients with high-risk esophageal varices." | 2.74 | Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. ( Ferguson, JW; Forrest, EH; Hayes, PC; Hislop, WS; Kochar, N; Leithead, JA; McAvoy, NC; Mills, PR; Stanley, AJ; Therapondos, G; Tripathi, D, 2009) |
| "Carvedilol is a relatively safe, effective portal hypotensive agent, both acutely and over 7 days, but not superior to propranolol, at least in Indians." | 2.70 | Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics. ( Biswas, PK; Das, D; De, BK; Maity, AK; Majumdar, D; Mandal, SK; Sen, S, 2002) |
| "Carvedilol was more efficacious than traditional NSBBs in decreasing the variceal rebleeding rate [odds ratio (OR): 0." | 2.61 | The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis. ( Chen, L; Ge, K; Yang, J; Yang, JL, 2019) |
| "Recent advances in the pharmacologic treatment of portal hypertension have mainly focused on modifying an increased intrahepatic resistance through nitric oxide and/or modulation of vasoactive substances." | 2.61 | Pharmacologic Management of Portal Hypertension. ( Bunchorntavakul, C; Reddy, KR, 2019) |
| "Frequently, relevant liver fibrosis is diagnosed by non-invasive methods (e." | 2.58 | [Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures]. ( Benten, D; Karkmann, K; Kluwe, J; Piecha, F; Rünzi, AC; Schulz, L; von Wulffen, M; Wege, H, 2018) |
| "Thus, optimal treatment of portal hypertension requires a strategy that takes into account the clinical stage of the disease and all the major variables that affect the risk of progression to the next stage and death." | 2.55 | Prevention and treatment of variceal haemorrhage in 2017. ( Berzigotti, A; Bosch, J; Brunner, F, 2017) |
| "Development of bleeding gastroesophageal varices is a serious consequence of portal hypertension secondary to cirrhosis." | 2.42 | Evaluation of carvedilol for the treatment of portal hypertension. ( Hemstreet, BA, 2004) |
| "Treatment of portal hypertension is evolving based on randomised controlled trials." | 2.42 | Management of portal hypertension. ( Burroughs, AK; Patch, DW; Samonakis, DN; Thalheimer, U; Triantos, CK, 2004) |
| "Treatment with carvedilol had an inverse relation with SDANN." | 1.91 | Heart rate variability is associated with disease severity and portal hypertension in cirrhosis. ( Amodio, E; Basso, MG; Cabibbo, G; Calvaruso, V; Casuccio, A; Craxì, A; Daidone, M; Di Raimondo, D; Licata, M; Miceli, G; Pennisi, G; Petta, S; Pinto, A; Pintus, C; Simone, F; Tuttolomondo, A; Velardo, M, 2023) |
| "Propranolol was used for secondary UVB prophylaxis in 43 (75." | 1.72 | Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis. ( Cançado, GGL; Cardoso, JB; Couto, CA; de Abreu, ES; Faria, LC; Ferrari, TCA; Lima, AMC; Nardelli, MJ; Osório, FMF, 2022) |
| "Carvedilol was shown to have a positive effect on gastric varices without significant adverse effects." | 1.56 | CARVEDILOL AS PRIMARY PROPHYLAXIS FOR GASTRIC VARICEAL BLEEDING IN PORTAL HYPERTENSION MODEL IN RATS. ( Bertoldi, AS; Brighenti, LMV; Coltro, GA; Fauat, NI; Guetter, CR; Kubrusly, FB; Kubrusly, LF; Marques, CAM; Vosgerau, LM, 2020) |
| "Carvedilol 12." | 1.48 | Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study. ( Ferlitsch, A; Kivaranovic, D; Mandorfer, M; Paternostro, R; Peck-Radosavljevic, M; Reiberger, T; Schwarzer, R; Trauner, M, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.79) | 18.2507 |
| 2000's | 5 (8.93) | 29.6817 |
| 2010's | 30 (53.57) | 24.3611 |
| 2020's | 20 (35.71) | 2.80 |
| Authors | Studies |
|---|---|
| de Abreu, ES | 1 |
| Nardelli, MJ | 1 |
| Lima, AMC | 1 |
| Cardoso, JB | 1 |
| Osório, FMF | 1 |
| Ferrari, TCA | 1 |
| Faria, LC | 1 |
| Couto, CA | 1 |
| Cançado, GGL | 1 |
| Dunne, PDJ | 1 |
| Young, D | 2 |
| Chuah, CS | 2 |
| Hayes, PC | 6 |
| Tripathi, D | 8 |
| Leithead, J | 1 |
| Smith, LA | 1 |
| Gaya, DR | 2 |
| Forrest, E | 1 |
| Stanley, AJ | 5 |
| Villanueva, C | 2 |
| Torres, F | 2 |
| Sarin, SK | 4 |
| Shah, HA | 2 |
| Brujats, A | 1 |
| Rodrigues, SG | 1 |
| Bhardwaj, A | 3 |
| Azam, Z | 2 |
| Jindal, A | 4 |
| Abid, S | 2 |
| Alvarado, E | 1 |
| Bosch, J | 7 |
| Kimer, N | 1 |
| Hobolth, L | 2 |
| Jachs, M | 1 |
| Hartl, L | 1 |
| Simbrunner, B | 1 |
| Bauer, D | 1 |
| Paternostro, R | 2 |
| Balcar, L | 1 |
| Hofer, B | 1 |
| Pfisterer, N | 1 |
| Schwarz, M | 1 |
| Scheiner, B | 1 |
| Stättermayer, AF | 1 |
| Pinter, M | 3 |
| Trauner, M | 4 |
| Mandorfer, M | 4 |
| Reiberger, T | 7 |
| Gralnek, IM | 1 |
| Camus Duboc, M | 1 |
| Garcia-Pagan, JC | 2 |
| Fuccio, L | 1 |
| Karstensen, JG | 1 |
| Hucl, T | 1 |
| Jovanovic, I | 1 |
| Awadie, H | 1 |
| Hernandez-Gea, V | 2 |
| Tantau, M | 1 |
| Ebigbo, A | 1 |
| Ibrahim, M | 1 |
| Vlachogiannakos, J | 1 |
| Burgmans, MC | 1 |
| Rosasco, R | 1 |
| Triantafyllou, K | 1 |
| Le Boutillier, C | 1 |
| Ahmed, H | 1 |
| Patel, VC | 2 |
| McPhail, M | 1 |
| Carter, B | 2 |
| Ward, C | 1 |
| Lawrence, V | 1 |
| McPhail, MJW | 1 |
| Gillespie, SL | 1 |
| Hanrahan, TP | 1 |
| Rockey, DC | 1 |
| Majumdar, A | 1 |
| Miceli, G | 1 |
| Calvaruso, V | 1 |
| Casuccio, A | 1 |
| Pennisi, G | 1 |
| Licata, M | 1 |
| Pintus, C | 1 |
| Basso, MG | 1 |
| Velardo, M | 1 |
| Daidone, M | 1 |
| Amodio, E | 1 |
| Petta, S | 1 |
| Simone, F | 1 |
| Cabibbo, G | 1 |
| Di Raimondo, D | 1 |
| Craxì, A | 1 |
| Pinto, A | 1 |
| Tuttolomondo, A | 1 |
| Turco, L | 1 |
| Vitale, G | 1 |
| La Mura, V | 1 |
| Tapper, EB | 1 |
| Parikh, ND | 1 |
| Muhammad Farooq Hanif, - | 1 |
| Raja Omer Fiaz, - | 1 |
| Muhammad Adnan Iqbal, - | 1 |
| Aneeza Ilyas, - | 1 |
| Maria, - | 1 |
| Khalid Mahmud Khan, - | 1 |
| Nooman Gilani, - | 1 |
| Kumar, M | 2 |
| Kainth, S | 1 |
| Choudhury, A | 1 |
| Maiwall, R | 2 |
| Mitra, LG | 1 |
| Saluja, V | 1 |
| Agarwal, PM | 1 |
| Shasthry, SM | 2 |
| Kumar, G | 3 |
| Bunchorntavakul, C | 1 |
| Reddy, KR | 1 |
| Huang, X | 1 |
| Fan, X | 1 |
| Chen, S | 1 |
| Chen, WC | 3 |
| Hou, MC | 2 |
| Vijayaraghavan, R | 1 |
| Arora, V | 1 |
| Choudhary, A | 2 |
| McDowell, HR | 1 |
| Forrest, EH | 3 |
| Bertoldi, AS | 1 |
| Guetter, CR | 1 |
| Coltro, GA | 1 |
| Vosgerau, LM | 1 |
| Brighenti, LMV | 1 |
| Fauat, NI | 1 |
| Kubrusly, FB | 1 |
| Marques, CAM | 1 |
| Kubrusly, LF | 1 |
| Poyner, C | 1 |
| Mathers, J | 1 |
| Püspök, A | 1 |
| Schoder, M | 1 |
| Baumann-Durchschein, F | 1 |
| Bucsics, T | 1 |
| Datz, C | 1 |
| Dolak, W | 1 |
| Ferlitsch, A | 4 |
| Finkenstedt, A | 1 |
| Graziadei, I | 1 |
| Hametner, S | 1 |
| Karnel, F | 1 |
| Krones, E | 1 |
| Maieron, A | 1 |
| Peck-Radosavljevic, M | 4 |
| Rainer, F | 1 |
| Schwabl, P | 2 |
| Stadlbauer, V | 1 |
| Stauber, R | 1 |
| Tilg, H | 1 |
| Zoller, H | 1 |
| Schöfl, R | 1 |
| Fickert, P | 1 |
| Abd ElRahim, AY | 1 |
| Fouad, R | 1 |
| Khairy, M | 1 |
| Elsharkawy, A | 1 |
| Fathalah, W | 1 |
| Khatamish, H | 1 |
| Khorshid, O | 1 |
| Moussa, M | 1 |
| Seyam, M | 1 |
| Baiges, A | 1 |
| Karkmann, K | 1 |
| Piecha, F | 1 |
| Rünzi, AC | 1 |
| Schulz, L | 1 |
| von Wulffen, M | 1 |
| Benten, D | 1 |
| Kluwe, J | 1 |
| Wege, H | 1 |
| Robertson, M | 1 |
| Hayes, P | 1 |
| Schwarzer, R | 1 |
| Kivaranovic, D | 1 |
| Zacharias, AP | 1 |
| Jeyaraj, R | 1 |
| Bendtsen, F | 1 |
| Gluud, LL | 1 |
| Morgan, MY | 1 |
| Kim, HY | 1 |
| So, YH | 1 |
| Kim, W | 1 |
| Ahn, DW | 1 |
| Jung, YJ | 1 |
| Woo, H | 1 |
| Kim, D | 1 |
| Kim, MY | 2 |
| Baik, SK | 2 |
| Hsin, IF | 1 |
| Chen, PH | 1 |
| Hsu, PI | 1 |
| Wang, YP | 1 |
| Cheng, JS | 1 |
| Lin, HS | 1 |
| Lee, FY | 1 |
| Yang, J | 1 |
| Ge, K | 1 |
| Chen, L | 1 |
| Yang, JL | 1 |
| Rauf, J | 1 |
| Hamid, S | 1 |
| Jafri, W | 1 |
| Khalid, A | 1 |
| Ismail, FW | 1 |
| Parkash, O | 1 |
| Subhan, A | 1 |
| Munir, SM | 1 |
| Simonetto, DA | 1 |
| Shah, VH | 1 |
| Kamath, PS | 1 |
| Dickson, S | 1 |
| Mills, PR | 2 |
| Leithead, JA | 2 |
| MacBeth, K | 1 |
| Smith, L | 1 |
| Suzuki, H | 1 |
| Li, T | 1 |
| Ke, W | 1 |
| Sun, P | 1 |
| Chen, X | 1 |
| Belgaumkar, A | 1 |
| Huang, Y | 1 |
| Xian, W | 1 |
| Li, J | 1 |
| Zheng, Q | 1 |
| Kedarisetty, CK | 1 |
| Vashishtha, C | 1 |
| Bhadoria, AS | 1 |
| Bhatia, V | 1 |
| Kim, SG | 1 |
| Kim, TY | 1 |
| Sohn, JH | 1 |
| Um, SH | 1 |
| Seo, YS | 1 |
| Jang, JY | 1 |
| Jeong, SW | 1 |
| Lee, B | 1 |
| Kim, YS | 1 |
| Suk, KT | 1 |
| Kim, DJ | 1 |
| Gupta, V | 1 |
| Rawat, R | 1 |
| Saraya, A | 1 |
| Brunner, F | 1 |
| Berzigotti, A | 1 |
| Steib, CJ | 1 |
| Gerbes, AL | 1 |
| Ferguson, JW | 1 |
| Kochar, N | 1 |
| Therapondos, G | 1 |
| McAvoy, NC | 1 |
| Hislop, WS | 1 |
| Tsochatzis, EA | 1 |
| Triantos, CK | 2 |
| Burroughs, AK | 2 |
| Wang, CC | 1 |
| Kao, JH | 1 |
| Payer, BA | 2 |
| Homoncik, M | 1 |
| Lo, GH | 1 |
| Wang, HM | 1 |
| Yu, HC | 1 |
| Ulbrich, G | 1 |
| Heinisch, BB | 1 |
| Kramer, L | 1 |
| Hemstreet, BA | 1 |
| Samonakis, DN | 1 |
| Thalheimer, U | 1 |
| Patch, DW | 1 |
| Bañares, R | 1 |
| Moitinho, E | 1 |
| Piqueras, B | 1 |
| Casado, M | 1 |
| de Diego, A | 1 |
| De, BK | 1 |
| Das, D | 1 |
| Sen, S | 1 |
| Biswas, PK | 1 |
| Mandal, SK | 1 |
| Majumdar, D | 1 |
| Maity, AK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Nonselective Beta Blockers vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices[NCT02583698] | 136 participants (Actual) | Interventional | 2015-10-01 | Completed | |||
| A Prospective Randomized Study to Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices[NCT02465645] | 220 participants (Actual) | Interventional | 2015-06-01 | Completed | |||
| A Prospective Multicenter Cohort Study on the Timing of Emergency Endoscopy for Esophagogastric Variceal Bleeding in Cirrhosis[NCT04932200] | 608 participants (Anticipated) | Observational | 2021-06-15 | Not yet recruiting | |||
| Timing of Endoscopic Intervention in Patients With Cirrhosis With Acute Variceal Upper Gastrointestinal Hemorrhage (TEACH Trial): a Randomized Clinical Trial[NCT04786743] | 400 participants (Anticipated) | Interventional | 2021-04-20 | Recruiting | |||
| Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study[NCT04543643] | Phase 3 | 288 participants (Anticipated) | Interventional | 2021-11-01 | Not yet recruiting | ||
| Prospective Cohort Study to Evaluate Long-term Outcomes in Patients With Liver Cirrhosis of Boramae Hospital[NCT01943318] | 500 participants (Actual) | Observational [Patient Registry] | 2013-01-31 | Completed | |||
| Spleen Stiffness Combined With Liver Stiffness Measured by Two-dimensional Shear Wave Elastography for the Screening of High-risk Varices in Patients With Compensated Advanced Chronic Liver Disease (CHESS2004)[NCT04546360] | 300 participants (Anticipated) | Observational [Patient Registry] | 2020-09-08 | Recruiting | |||
| Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding[NCT02504723] | Phase 4 | 121 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Prospective, Double-blind, Randomized Placebo-controlled Trial of Carvedilol for Early Primary Prophylaxis of Esophageal Varices in Cirrhosis.[NCT01196507] | 140 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| Transient Elastography (FibroTouch) for Assessing Risk of Gastroesophageal Varices Bleeding in Patients With Compensated Cirrhosis (Pan-CHESS1801): An International Multicenter Study[NCT03778775] | 200 participants (Anticipated) | Observational | 2018-12-14 | Recruiting | |||
| Prevalence of Metabolic Associated Fatty Liver Disease in Patients With Type 2 Diabetes in Jiangsu Province of China: a Prospective, Multicenter, Real-world Study[NCT05597709] | 2,900 participants (Anticipated) | Observational | 2022-07-01 | Recruiting | |||
| Detachable String Magnetically Controlled Capsule Endoscopy for Detecting High-risk Varices in Compensated Advanced Chronic Liver Disease (CHESS1801): A Prospective Multicenter Study[NCT03749954] | 105 participants (Actual) | Observational | 2018-11-09 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
All adverse effects during the study period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 32 |
| Cyanoacrylate Injection | 9 |
All cause mortality or liver transplantation during the study period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 13 |
| Cyanoacrylate Injection | 20 |
All upper gastrointestinal bleeding during the follow-up period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 17 |
| Cyanoacrylate Injection | 29 |
Rebleeding from gastric varices during the follow-up period (NCT02504723)
Timeframe: Within 6 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Cyanoacrylate Injection Plus Carvedilol | 14 |
| Cyanoacrylate Injection | 21 |
17 reviews available for carvedilol and Esophageal Varices
| Article | Year |
|---|---|
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Humans; Hypertensi | 2022 |
Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Lo | 2023 |
Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Reply to: "Carvedilol in patients with compensated cirrhosis: The ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices".
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Lo | 2023 |
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc | 2023 |
Pharmacologic Management of Portal Hypertension.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Anticoagulants; Antihypertensi | 2019 |
Pharmacologic prevention of variceal bleeding and rebleeding.
Topics: Adrenergic beta-Antagonists; Atorvastatin; Carbazoles; Carvedilol; Esophageal and Gastric Varices; G | 2018 |
[Management of compensated liver cirrhosis 2018 - Evidence based prophylactic measures].
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Germany; Hepatic Encephalop | 2018 |
Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.
Topics: Adrenergic beta-Antagonists; Adult; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hem | 2018 |
The efficacy comparison of carvedilol plus endoscopic variceal ligation and traditional, nonselective β-blockers plus endoscopic variceal ligation in cirrhosis patients for the prevention of variceal rebleeding: a meta-analysis.
Topics: Adrenergic beta-Antagonists; Carvedilol; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices | 2019 |
Primary prophylaxis of variceal bleeding.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Esopha | 2014 |
Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis.
Topics: Antihypertensive Agents; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Esophageal and Ga | 2016 |
Beta blockers and cirrhosis, 2016.
Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Ascites; Carbazoles; Carvedilol; Esophageal and Ga | 2017 |
Prevention and treatment of variceal haemorrhage in 2017.
Topics: Adrenergic beta-Antagonists; Anti-Bacterial Agents; Balloon Occlusion; Carbazoles; Carvedilol; Endos | 2017 |
Evaluation of carvedilol for the treatment of portal hypertension.
Topics: Adrenergic Antagonists; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Fibrosis; Humans; Hy | 2004 |
Management of portal hypertension.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Humans; Hyperte | 2004 |
18 trials available for carvedilol and Esophageal Varices
| Article | Year |
|---|---|
Carvedilol versus endoscopic band ligation for secondary prophylaxis of variceal bleeding-long-term follow-up of a randomised control trial.
Topics: Carvedilol; Esophageal and Gastric Varices; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; | 2022 |
Comparison of carvedilol and propranolol for primary prophylaxis of esophageal variceal bleed in cirrhotic patients.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2023 |
Treatment with carvedilol improves survival of patients with acute-on-chronic liver failure: a randomized controlled trial.
Topics: Acute-On-Chronic Liver Failure; Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Carv | 2019 |
Hemodynamic Effects of Adding Simvastatin to Carvedilol for Primary Prophylaxis of Variceal Bleeding: A Randomized Controlled Trial.
Topics: Adrenergic beta-Antagonists; Adult; Carvedilol; Drug Therapy, Combination; Esophageal and Gastric Va | 2020 |
Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Follow-Up Studies; Gastroin | 2021 |
Exploring patients' perceptions and experiences of treatments for the prevention of variceal bleeding: a qualitative study.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Ligation; Perceptio | 2021 |
Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Egypt; Esophageal and Gastric Vari | 2018 |
Carvedilol vs. esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage: a multicentre randomized controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; | 2014 |
Multicentre randomised controlled study comparing carvedilol with variceal band ligation in the prevention of variceal rebleeding.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Esophageal and Gastric V | 2014 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adult; Carbazoles; Carvedilol; Disease Progression; Disease | 2017 |
A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis.
Topics: Adult; Antihypertensive Agents; Ascites; Carbazoles; Carvedilol; End Stage Liver Disease; Esophageal | 2016 |
Carvedilol versus propranolol effect on hepatic venous pressure gradient at 1 month in patients with index variceal bleed: RCT.
Topics: Adult; Antihypertensive Agents; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Esophagoscop | 2017 |
Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Fe | 2009 |
Gastrointestinal bleeding: Carvedilol-the best beta-blocker for primary prophylaxis?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Endoscopy; Esophageal and Gastric Varices; Gast | 2009 |
Randomized, controlled trial of carvedilol versus nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Carbazoles; Carvedilol; Chi-Square Distribution; Dru | 2012 |
Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; | 2013 |
Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antihypertensive Agents; Blood Pressure; | 1999 |
Acute and 7-day portal pressure response to carvedilol and propranolol in cirrhotics.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Carbazole | 2002 |
21 other studies available for carvedilol and Esophageal Varices
| Article | Year |
|---|---|
Carvedilol as secondary prophylaxis for variceal bleeding in hepatosplenic schistosomiasis.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Ligation; Propranol | 2022 |
Editorial: timing of carvedilol - promoting survivors in cirrhosis.
Topics: Carvedilol; Esophageal and Gastric Varices; Humans; Liver Cirrhosis; Survivors | 2022 |
Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2023 |
Carvedilol as Best β-Blocker for Secondary Prophylaxis of Variceal Bleeding: Are We There, or Not Yet?
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2023 |
Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.
Topics: Carvedilol; Cyanoacrylates; Endoscopy, Gastrointestinal; Esophageal and Gastric Varices; Gastrointes | 2022 |
General practitioner perspectives on factors that influence implementation of secondary care-initiated treatment in primary care: Exploring implementation beyond the context of a clinical trial.
Topics: Adrenergic beta-Antagonists; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage | 2022 |
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis.
Topics: Ascites; Carvedilol; Cross-Sectional Studies; Esophageal and Gastric Varices; Heart Rate; Humans; Hy | 2023 |
Individualized Treatment of Gastric Varices in Cirrhotic Portal Hypertension.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Porta | 2019 |
Reply.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Re | 2019 |
KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications.
Topics: Adrenergic beta-Antagonists; Ammonia; Anti-Bacterial Agents; Carvedilol; Disaccharides; Endoscopy, G | 2020 |
CARVEDILOL AS PRIMARY PROPHYLAXIS FOR GASTRIC VARICEAL BLEEDING IN PORTAL HYPERTENSION MODEL IN RATS.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Carvedilol; Esophageal and Gastric Va | 2020 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Austrian consensus guidelines on the management and treatment of portal hypertension (Billroth III).
Topics: Austria; Carbazoles; Carvedilol; Comorbidity; Early Medical Intervention; Esophageal and Gastric Var | 2017 |
Primary prophylaxis of variceal bleeding.
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Endoscopy; Esophageal and Gastric Varices; Gast | 2018 |
Carvedilol for reducing portal pressure in primary prophylaxis of variceal bleeding: a dose-response study.
Topics: Antihypertensive Agents; Carvedilol; Dose-Response Relationship, Drug; Esophageal and Gastric Varice | 2018 |
Editorial: optimal dose of carvedilol in portal hypertension…nearly there.
Topics: Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hypertension, Porta | 2018 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices.
Topics: Adrenergic beta-Antagonists; Carvedilol; Chemoprevention; Clinical Decision Rules; Elasticity Imagin | 2019 |
Addition of Carvedilol to Gastric Variceal Obturation Does Not Decrease Recurrence of Gastric Variceal Bleeding in Patients With Cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Carvedilol; Endoscopy, Gastrointestinal | 2019 |
Secondary prophylaxis for variceal bleeding: carvedilol vs. propranolol.
Topics: Adrenergic beta-Antagonists; Blood Pressure; Carbazoles; Carvedilol; Drug Monitoring; Esophageal and | 2017 |
Carvedilol versus variceal band ligation for prevention of the first variceal bleed.
Topics: Carbazoles; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Hyperte | 2010 |
Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Elasticity; Elasticity Imaging Technique | 2012 |
Carvedilol: the β-blocker of choice for portal hypertension?
Topics: Adrenergic beta-Antagonists; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Female; Gastroi | 2013 |